ChiCTR2300072431 版本V1.1 版本创建时间2023/08/01 17:22:16 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300072431 

最近更新日期:

Date of Last Refreshed on:

2023-06-13 16:24:52 

注册时间:

Date of Registration:

2023-06-13 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

小剂量艾司氯胺酮对比丙泊酚降低眼科日间患儿苏醒期急性躁动的效果研究:一项随机单盲对照实验

Public title:

Effect of low-dose Esketamine versus propofol on emergence agitation during awakening in children with daytime ophthalmology: a randomized single-blind controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

小剂量艾司氯胺酮对比丙泊酚降低眼科日间患儿苏醒期急性躁动的效果研究:一项随机单盲对照实验

Scientific title:

Effect of low-dose Esketamine versus propofol on emergence agitation during awakening in children with daytime ophthalmology: a randomized single-blind controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

金玉 

研究负责人:

张娜 

Applicant:

Yu Jin 

Study leader:

Na Zhang 

申请注册联系人电话:

Applicant telephone:

+86 177 0560 4768

研究负责人电话:

Study leader's telephone:

+86 135 6040 9867

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1449177071@qq.com

研究负责人电子邮件:

Study leader's E-mail:

na999666@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市人民中路318号

研究负责人通讯地址:

广东省广州市人民中路318号

Applicant address:

Renmin Middle Road 318, Yuexiu District, Guangzhou 510623, China

Study leader's address:

Renmin Middle Road 318, Yuexiu District, Guangzhou 510623, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广州市妇女儿童医疗中心

Applicant's institution:

Guangzhou Women and Children’s Medical Center

研究负责人所在单位:

广州市妇女儿童医疗中心

Affiliation of the Leader:

Guangzhou Women and Children’s Medical Center

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

穗妇儿 科伦 批字[2023]第110A01号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广州市妇女儿童医疗中心伦理委员会

Name of the ethic committee:

The Research ethics committee of Guangzhou Women and Children's Medical Center

伦理委员会批准日期:

Date of approved by ethic committee:

2023-04-19 00:00:00

伦理委员会联系人:

斯文越

Contact Name of the ethic committee:

Wenyue Si

伦理委员会联系地址:

广东省广州市天河区珠江新城华强路9号保利克洛维503室

Contact Address of the ethic committee:

Room 503, Poly Clowey, 9 Huaqiang Road, Zhujiang New Town, Tianhe District, Guangzhou 510623, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 3836 7270

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广州市妇女儿童医疗中心

Primary sponsor:

Guangzhou Women and Children’s Medical Center

研究实施负责(组长)单位地址:

广东省广州市人民中路318号

Primary sponsor's address:

Renmin Middle Road 318, Yuexiu District, Guangzhou 510623, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广州市妇女儿童医疗中心

具体地址:

广东省广州市人民中路318号

Institution
hospital:

Guangzhou Women and Children’s Medical Center

Address:

Renmin Middle Road 318, Yuexiu District, Guangzhou 510623, China

经费或物资来源:

Source(s) of funding:

None

Target disease:

emergence agitation

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探讨小剂量艾司氯胺酮对比丙泊酚用于日间眼科患儿苏醒期急性躁动的发生情况  

Objectives of Study:

Objective To investigate the occurrence of low dose esketamine versus propofol in emergence agitation in daytime ophthalmic children

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.患儿法定监护人签署知情同意书 2.眼科日间手术(睑板腺囊肿、倒睫、斜视) 3.单眼手术 4.ASA I-II级 5.年龄3-7周岁

Inclusion criteria

1. The legal guardian of the child signs the informed consent 2. Ophthalmic day surgery (meibomian gland cyst, trichiasis, strabismus) 3. Monocular surgery 4.ASA Grade I-II 5. Ages 3-7

排除标准:

1.对本研究使用药物过敏 2.有本药物使用禁忌症 3.有精神类疾病 4.患儿或患儿法定监护人中途退出此试验或拒绝配合资料收集

Exclusion criteria:

1. Allergy to drugs used in this study 2. There are contraindications for the use of this drug 3. You have mental illness 4. The child or the legal guardian of the child withdrew from the experiment or refused to cooperate with the data collection

研究实施时间:

Study execute time:

From 2023-07-01 00:00:00 To 2025-05-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-07-01 00:00:00 To 2025-05-01 00:00:00  

干预措施:

Interventions:

组别:

艾司氯胺酮组

样本量:

78

Group:

Esketamine group

Sample size:

干预措施:

0.3mg/kg艾司氯胺酮

干预措施代码:

Intervention:

0.3mg/kg esketamine

Intervention code:

组别:

丙泊酚组

样本量:

78

Group:

Propofol group

Sample size:

干预措施:

1mg/kg丙泊酚

干预措施代码:

Intervention:

1mg/kg propofo

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

广州 

Country:

China 

Province:

Guangdong 

City:

Guangzhou 

单位(医院):

广州市妇女儿童医疗中心 

单位级别:

三甲 

Institution
hospital:

Guangzhou Women and Children’s Medical Center

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

苏醒期急性躁动

指标类型:

主要指标

Outcome:

emergence agitation

Type:

Primary indicator

测量时间点:

麻醉恢复室期间

测量方法:

Aono四分评级法

Measure time point of outcome:

During the anesthesia recovery room

Measure method:

Aono four point rating method

指标中文名:

苏醒时间(分)

指标类型:

次要指标

Outcome:

Recovery time (minutes)

Type:

Secondary indicator

测量时间点:

麻醉恢复室期间

测量方法:

Measure time point of outcome:

During the anesthesia recovery room

Measure method:

指标中文名:

拔管时间(分)

指标类型:

次要指标

Outcome:

Extubation time (minutes)

Type:

Secondary indicator

测量时间点:

麻醉恢复室期间

测量方法:

Measure time point of outcome:

During the anesthesia recovery room

Measure method:

指标中文名:

PACU停留时间(分)

指标类型:

次要指标

Outcome:

PACU residence time (minutes)

Type:

Secondary indicator

测量时间点:

麻醉恢复室期间

测量方法:

Measure time point of outcome:

During the anesthesia recovery room

Measure method:

指标中文名:

苏醒期EA处理丙泊酚追加例数

指标类型:

次要指标

Outcome:

Number of cases of EA treated with propofol addition during recovery period

Type:

Secondary indicator

测量时间点:

麻醉恢复室期间

测量方法:

Measure time point of outcome:

During the anesthesia recovery room

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 3 years
最大 Max age 7 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

项目负责人提前用计算机生成随机数表

Randomization Procedure (please state who generates the random number sequence and by what method):

The project leader uses the computer to generate a random number table in advance

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

采用单盲试验,仅研究观察评价者盲即麻醉恢复室(PACU)间观察、评价、处理患儿EA的麻醉护士不了解试验分组情况,但研究者、参与试验的患儿、患儿法定监护人、眼科医师、麻醉医师可以知道分组情况。

Blinding:

The single-blind trial was conducted, and only the anesthesiologists who observed, evaluated, and handled EA in the blind anesthesia recovery room (PACU) did not know the grouping status of the trial, but the researchers, the children participating in the trial, the legal guardians of the children, the ophthalmologists, and the anesthesiologists could know the grouping status.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2025年5月1日,上传原始数据到临床试验公共管理平台 http://www.medresman.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

May 1, 2025, the original data was uploaded to ResMan http://www.medresman.org.cn

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

All subject data will be collected with redcap and stored under lock and seal by the person in charge, without disclosing any private information of the patients.

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

All subject data will be collected with redcap and stored under lock and seal by the person in charge, without disclosing any private information of the patients.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-06-13 16:24:28